Glory View Technology (301396.SZ) plans to buy back company shares for between 30 million and 50 million yuan.

18:00 03/08/2026

Hongjing Technology (301396.SZ) announced that the company plans to use its own funds to repurchase shares through centralized bidding, intended for future implementation of an employee stock ownership plan or equity incentives. The funds for the share repurchase will not be less than 30 million yuan (inclusive) and not more than 50 million yuan (inclusive). The repurchase price for the shares will not exceed 260 yuan per share (inclusive).

Glory View Technology (301396.SZ) announced that the company plans to use its own funds to repurchase shares through centralized bidding transactions, for the future implementation of an employee stock ownership plan or equity incentives. The funds allocated for the share repurchase will be no less than 30 million yuan (inclusive) and no more than 50 million yuan (inclusive). The repurchase price will not exceed 260 yuan per share (inclusive).

ASCLETIS-B (01672) announced that its GLP-1 oral small molecule ASC30 has launched global Phase III clinical studies and released positive preclinical data for its first-in-class oral small molecule GLP-1/GIP/insulin fixed-dose combination formulation.

Porton Pharma Solutions (300363.SZ) subsidiary obtains drug manufacturing license.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.

Porton Pharma Solutions (300363.SZ) subsidiary obtains drug manufacturing license.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.